Compare Duke Energy Corp (DUK) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duke Energy Corp vs Neurocrine Biosciences Inc — how do they compare? Duke Energy Corp trades at $116.65 (market cap $91.10B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: Duke Energy Corp is far larger — about 6.3× Neurocrine Biosciences Inc's market cap, and Duke Energy Corp pays a 3.71% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Duke Energy Corp for 74 Days and Neurocrine Biosciences Inc for 23 Days on average.
| DUK | NBIX | |
|---|---|---|
Market Cap | $91.10B | $14.36B |
Volume | 4,199,050 | 1,237,180 |
Sector | Utilities | Health |
52-Week High | $133.46 | $185.50 |
52-Week Low | $113.23 | $123.10 |
Typical Hold Time | 74 Days | 23 Days |
Enterprise Value | $183.61B | $14.37B |
Dividend Yield | 3.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $116.65, up 1.0% today, with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with a 15.78% net income margin and a dividend yield supported by recent $1.09 payouts. Revenue growth is steady, reaching $32.24B in 2025, while analyst consensus targets $134.44, implying upside potential.
The outlook is positive due to earnings momentum and data center demand, but risks include rising Treasury yields pressuring utility stocks and high debt levels. Investors should weigh the reliable dividend against interest rate sensitivity and capital expenditure needs for growth initiatives.
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
